الصفحة الرئيسية>>Signaling Pathways>> Obesity, Appetite Control & Diabetes>> Diabetes>>10(R)-PAHSA

10(R)-PAHSA

رقم الكتالوجGC40317

10(R)-PAHSA is a stereoisomer of 10-PAHSA, an endogenous lipid that belongs to a collection of branched fatty acid esters of hydroxy fatty acids (FAHFAs).

Products are for research use only. Not for human use. We do not sell to patients.

10(R)-PAHSA التركيب الكيميائي

الحجم السعر المخزون الكميّة
500μg
427٫00
متوفر
1mg
811٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

10(R)-PAHSA is a stereoisomer of 10-PAHSA , an endogenous lipid that belongs to a collection of branched fatty acid esters of hydroxy fatty acids (FAHFAs). It is an FAHFA in which palmitic acid is esterified to 10-hydroxy stearic acid. Among the FAHFA family members, PAHSAs are the most abundant in the adipose tissue of glucose tolerant AG4OX mice, which overexpress the Glut4 glucose transporter specifically in adipose tissue. A study using synthesized (R)- and (S)- stereoisomers of 9-PAHSA reported that the 9(R)-PAHSA is the predominant form that accumulates in adipose tissues in vivo. Also, cell lines favor the production of 9(R)-PAHSA and carboxyl ester lipase selectively hydrolyzes 9(S)-PAHSA .The use of this optically-active FAHFA product (the "Product") is covered by U.S. Patent No. 10,240,025 and corresponding foreign counterpart applications.

مراجعات

Review for 10(R)-PAHSA

Average Rating: 5 ★★★★★ (Based on Reviews and 27 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 10(R)-PAHSA

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.